{"id":5659,"date":"2013-08-06T12:41:10","date_gmt":"2013-08-06T12:41:10","guid":{"rendered":"https:\/\/medicalcriteria.com\/web\/intravenous-immune-globulin\/"},"modified":"2025-05-13T20:27:55","modified_gmt":"2025-05-13T20:27:55","slug":"intravenous-immune-globulin","status":"publish","type":"post","link":"https:\/\/medicalcriteria.com\/web\/es\/intravenous-immune-globulin\/","title":{"rendered":"Inmunoglobulina Intravenosa en Enfermedades Autoinmunes e Inflamatorias"},"content":{"rendered":"<div class=\"7ca9444b8380138fe077da07353677a4\" data-index=\"1\" style=\"float: none; margin:0px 0 0px 0; text-align:center;\">\n<script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\r\n<!-- MC 2019- Horizontal -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-0127150553352455\"\r\n     data-ad-slot=\"3806776041\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script>\n<\/div>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Initially used for the treatment of immunodeficiencies, intravenous immunoglobulins (IVIg) have increasingly been used as immunomodulatory agent in autoimmune and inflammatory disorders.\">Inicialmente utilizado para el tratamiento de inmunodeficiencias, las inmunoglobulinas por v\u00eda intravenosa (<\/span><\/span><span id=\"result_box\" lang=\"es\"><span title=\"IVIg also has an impact on effector functions of immune cells.\">IgIV<\/span><\/span><span id=\"result_box\" lang=\"es\"><span title=\"Initially used for the treatment of immunodeficiencies, intravenous immunoglobulins (IVIg) have increasingly been used as immunomodulatory agent in autoimmune and inflammatory disorders.\">) cada vez son m\u00e1s utilizadas como agentes inmunomoduladores en trastornos autoinmunes e inflamatorias.\u00a0<\/span><span title=\"The mode of action of IVIg is enigmatic, probably involving Fc-dependent and\/or F(ab')2-dependent non-exclusive mechanisms of action.\">El modo de acci\u00f3n de las\u00a0<\/span><\/span><span id=\"result_box\" lang=\"es\"><span title=\"IVIg also has an impact on effector functions of immune cells.\">IgIV<\/span><\/span><span id=\"result_box\" lang=\"es\"><span title=\"The mode of action of IVIg is enigmatic, probably involving Fc-dependent and\/or F(ab')2-dependent non-exclusive mechanisms of action.\"> es enigm\u00e1tico, probablemente est\u00e9n involucrados la participaci\u00f3n de\u00a0<\/span><\/span><span id=\"result_box\" lang=\"es\"><span title=\"The mode of action of IVIg is enigmatic, probably involving Fc-dependent and\/or F(ab')2-dependent non-exclusive mechanisms of action.\">mecanismos no exclusivos dependientes<\/span><\/span><span id=\"result_box\" lang=\"es\"><span title=\"The mode of action of IVIg is enigmatic, probably involving Fc-dependent and\/or F(ab')2-dependent non-exclusive mechanisms of action.\">\u00a0de la fracci\u00f3n Fc y\/o F(ab&#8217;)2. Las\u00a0<\/span><span title=\"IVIg broadly interacts with the different components of the immune system: cytokines, complement, Fc receptors and several cell surface immunocompetent molecules.\">IgIV interact\u00faa ampliamente con los diferentes componentes del sistema inmune: citoquinas, complemento, receptores de Fc y varias mol\u00e9culas de superficie de c\u00e9lulas inmunocompetentes. Las\u00a0<\/span><span title=\"IVIg also has an impact on effector functions of immune cells.\">IgIV tambi\u00e9n tienen un impacto en las funciones efectoras de las c\u00e9lulas inmunes.\u00a0<\/span><span title=\"These mechanisms of action of IVIg reflect the importance of natural antibodies in the maintenance of immune homeostasis.\">Estos mecanismos de acci\u00f3n de la IgIV reflejan la importancia de los anticuerpos naturales en el mantenimiento de la homeostasis inmune.<\/span><\/span><br \/>\n<!--more--><br \/>\n<span title=\"Diseases for Which Intravenous Immune Globulin Has Been Shown to Be Beneficial\"><strong>Enfermedades para las cuales la inmunoglobulina intravenosa han demostrado beneficio<\/strong><\/span><\/p>\n<p><span title=\"FDA-approved indications\"><strong>Indicaciones aprobadas por la FDA<\/strong><br \/>\n<\/span><\/p>\n<ul>\n<li><span title=\"Primary immunodeficiency disease\">Enfermedad de inmunodeficiencia primaria<\/span><\/li>\n<li><span title=\"Chronic lymphocytic leukemia\">Leucemia linfoc\u00edtica cr\u00f3nica<\/span><\/li>\n<li><span title=\"Pediatric HIV infection\">Infecci\u00f3n pedi\u00e1trica del VIH<\/span><\/li>\n<li><span title=\"Kawasaki\u2019s disease\">Enfermedad de Kawasaki<\/span><\/li>\n<li><span title=\"Allogeneic bone marrow transplantation\">Trasplante<\/span><span title=\"Allogeneic bone marrow transplantation\">\u00a0alog\u00e9nico<\/span><span title=\"Allogeneic bone marrow transplantation\">\u00a0de m\u00e9dula \u00f3sea<\/span><\/li>\n<li><span title=\"Chronic inflammatory demyelinating polyneuropathy\">Polineuropat\u00eda desmielinizante inflamatoria cr\u00f3nica<\/span><\/li>\n<li><span title=\"or an ABO-incompatible donor\">Trasplante renal que involucra un receptor con elevado t\u00edtulo de anticuerpos o un donante ABO incompatible<\/span><\/li>\n<li><span title=\"Multifocal motor neuropathy\">Neuropat\u00eda motora multifocal<\/span><\/li>\n<\/ul>\n<p><span title=\"Multifocal motor neuropathy\"><br \/>\n<\/span><span title=\"Additional approved indications with criteria\"><strong>Indicaciones aprobadas adicionales con criterios<\/strong><\/span><br \/>\n<span title=\"Additional approved indications with criteria\"><br \/>\n<\/span><span title=\"Neuromuscular disorders\">Trastornos neuromusculares<br \/>\n<\/span><\/p>\n<ul>\n<li><span title=\"Guillain\u2013Barr\u00e9 syndrome\">S\u00edndrome de Guillain &#8211; Barr\u00e9<\/span><\/li>\n<li><span title=\"Relapsing\u2013remitting multiple sclerosis\">Reca\u00edda-remisi\u00f3n de esclerosis m\u00faltiple<\/span><\/li>\n<li><span title=\"Myasthenia gravis\">Miastenia gravis<\/span><\/li>\n<li><span title=\"Refractory polymyositis\">Polimiositis refractaria<\/span><\/li>\n<li><span title=\"Polyradiculoneuropathy\">Polirradiculoneuropat\u00eda<\/span><\/li>\n<li><span title=\"Lambert\u2013Eaton myasthenic syndrome\">S\u00edndrome miast\u00e9nico de Lambert-Eaton<\/span><\/li>\n<li><span title=\"Opsoclonus\u2013myoclonus\">Opsoclonus-mioclonus<\/span><\/li>\n<li><span title=\"Birdshot retinopathy\">Retinopat\u00eda perdigonada<\/span><\/li>\n<li><span title=\"Refractory dermatomyositis\">Dermatomiositis refractaria<\/span><\/li>\n<\/ul>\n<p><span title=\"Refractory dermatomyositis\">T<\/span><span title=\"Hematologic disorders\">rastornos hematol\u00f3gicos<br \/>\n<\/span><\/p>\n<ul>\n<li><span title=\"Autoimmune hemolytic anemia\">Anemia hemol\u00edtica autoinmune<\/span><\/li>\n<li><span title=\"Severe anemia associated with parvovirus B19\">Anemia grave asociada con el parvovirus B19<\/span><\/li>\n<li><span title=\"Autoimmune neutropenia\">Neutropenia autoinmune<\/span><\/li>\n<li><span title=\"Neonatal alloimmune thrombocytopenia\">Trombocitopenia neonatal aloinmune<\/span><\/li>\n<li><span title=\"HIV-associated thrombocytopenia\">Trombocitopenia asociada al VIH<\/span><\/li>\n<li><span title=\"Graft-versus-host disease\">Enfermedad de injerto contra hu\u00e9sped<\/span><\/li>\n<li><span title=\"bone marrow transplantation\">Infecci\u00f3n por citomegalovirus o neumon\u00eda intersticial en pacientes sometidos a trasplante de m\u00e9dula \u00f3sea<\/span><\/li>\n<\/ul>\n<p><span title=\"bone marrow transplantation\"><br \/>\n<\/span><span title=\"Dermatologic disorders\">Trastornos dermatol\u00f3gicos<br \/>\n<\/span><\/p>\n<ul>\n<li><span title=\"Pemphigus vulgaris\">P\u00e9nfigo vulgar<\/span><\/li>\n<li><span title=\"Pemphigus foliaceus\">P\u00e9nfigo foli\u00e1ceo<\/span><\/li>\n<li><span title=\"Bullous pemphigoid\">Penfigoide ampolloso<\/span><\/li>\n<li><span title=\"Mucous-membrane (cicatricial) pemphigoid\">Membrana mucosa\u00a0<\/span><span title=\"Mucous-membrane (cicatricial) pemphigoid\">penfigoide<\/span><span title=\"Mucous-membrane (cicatricial) pemphigoid\">\u00a0(cicatricial)<br \/>\n<\/span><\/li>\n<li><span title=\"Epidermolysis bullosa acquisita\">Epidermolisis bullosa adquirida<\/span><\/li>\n<li><span title=\"Toxic epidermal necrolysis or Stevens\u2013Johnson syndrome\">Necr\u00f3lisis epid\u00e9rmica t\u00f3xica o s\u00edndrome de Stevens-Johnson<\/span><\/li>\n<li><span title=\"Necrotizing fasciitis\">Fascitis necrotizante<\/span><\/li>\n<\/ul>\n<p><span title=\"Necrotizing fasciitis\"><br \/>\n<\/span><span title=\"* This is an abbreviated list of conditions approved under Medicare Part D or Aetna Clinical Policy Bulletin (2012).\">* Esta es una lista abreviada de las condiciones aprobadas por Medicare Parte D o Aetna Clinical Policy Bulletin (2012).\u00a0<\/span><span title=\"Criteria include medical certainty of diagnosis, medical necessity owing to the failure of usual treatments, contraindications to usual treatments, rapid progression or relapse, documentation of progress, and attempts to adjust drug dosages without improvement.\">Los criterios incluyen la certeza m\u00e9dica del diagn\u00f3stico, necesidad m\u00e9dica debido al fallo de los tratamientos habituales, contraindicaciones a los tratamientos habituales, progresi\u00f3n r\u00e1pida o reca\u00eddas, documentaci\u00f3n del progreso, y los intentos de ajustar las dosis de medicamentos sin mejor\u00eda.\u00a0<\/span><span title=\"FDA denotes Food and Drug Administration, and HIV human immunodeficiency virus.\">FDA d<\/span><span title=\"FDA denotes Food and Drug Administration, and HIV human immunodeficiency virus.\">enota Food and Drug Administration, y\u00a0<\/span><span title=\"FDA denotes Food and Drug Administration, and HIV human immunodeficiency virus.\">VIH\u00a0<\/span><span title=\"FDA denotes Food and Drug Administration, and HIV human immunodeficiency virus.\">virus de la inmunodeficiencia humana.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Bibliograf\u00eda:<\/strong><\/p>\n<ol>\n<li>Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012 Nov 22;367(21):2015-25. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23171098\/\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<li>Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005 Oct;142(1):1-11. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16178850\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<\/ol>\n<p>&nbsp;<\/p>\n<p>Creado Oct 16, 2013.<\/p>\n\n<div style=\"font-size: 0px; height: 0px; line-height: 0px; margin: 0; padding: 0; clear: both;\"><\/div>","protected":false},"excerpt":{"rendered":"<p>Inicialmente utilizado para el tratamiento de inmunodeficiencias, las inmunoglobulinas por v\u00eda intravenosa (IgIV) cada vez son m\u00e1s utilizadas como agentes inmunomoduladores en trastornos autoinmunes e inflamatorias.\u00a0El modo de acci\u00f3n de las\u00a0IgIV es enigm\u00e1tico, probablemente est\u00e9n involucrados la participaci\u00f3n de\u00a0mecanismos no exclusivos dependientes\u00a0de la fracci\u00f3n Fc y\/o F(ab&#8217;)2. Las\u00a0IgIV interact\u00faa ampliamente con los diferentes componentes del [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[289],"tags":[250,2032,1277,1276,2031,2030,294,2029,809,2028,2027,2026,2033],"class_list":["post-5659","post","type-post","status-publish","format-standard","hentry","category-immunology","tag-autoimmune","tag-autoinmunes","tag-diseases","tag-enfermedades","tag-gflobulina","tag-globulin","tag-immune","tag-inflamatorias","tag-inflammatory","tag-inmune","tag-intravenosa","tag-intravenous","tag-ivig"],"modified_by":"Guillermo Firman","_links":{"self":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts\/5659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/comments?post=5659"}],"version-history":[{"count":4,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts\/5659\/revisions"}],"predecessor-version":[{"id":8844,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts\/5659\/revisions\/8844"}],"wp:attachment":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/media?parent=5659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/categories?post=5659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/tags?post=5659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}